PHF6-altered T-ALL harbor epigenetic repressive switch at bivalent promoters and respond to 5-azacitidine and venetoclax.
Antoine PintonLucien CourtoisCharlotte DoubletAurélie Cabannes-HamyGuillaume P AndrieuCharlotte L SmithEstelle BalducciAgata CieslakAurore TouzartMathieu SimoninVéronique LhéritierFrançoise HuguetMarie BalsatHervé DombretPhilippe RousselotSalvatore SpicugliaElizabeth A MacintyreNicolas BoisselVahid AsnafiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Overall, our study supports the use of PHF6 alterations as a biomarker of sensitivity to 5-azacytidine and venetoclax combination in R/R T-ALL.